Compare Amphastar Pharmaceuticals Inc (AMPH) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Schwab US Dividend Equity ETF — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.21 (market cap $826.08M), while Schwab US Dividend Equity ETF trades at $32.61. The key difference: Schwab US Dividend Equity ETF is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | SCHD | |
|---|---|---|
Market Cap | $826.08M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $30.81 | $32.83 |
52-Week Low | $16.87 | $26.38 |
Enterprise Value | $1.22B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
SCHD trades at $32.40, up 0.43% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF focuses on U.S. dividend equities, offering a yield around 3.2%, and has shown strong performance in 2026, outpacing the S&P 500. Recent news highlights its appeal for long-term income investors, though some analysts note underperformance concerns versus broader indices.
Outlook remains positive for dividend-focused portfolios, supported by quality stock selection and low fees. Key risks include interest rate sensitivity and market rotation away from value stocks. Institutional sentiment is mixed, with bullish technicals contrasting with fundamental debates on total returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
